These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 23948957)

  • 1. Histopathology of prostate tissue after vascular-targeted photodynamic therapy for localized prostate cancer.
    Eymerit-Morin C; Zidane M; Lebdai S; Triau S; Azzouzi AR; Rousselet MC
    Virchows Arch; 2013 Oct; 463(4):547-52. PubMed ID: 23948957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapy.
    Moore CM; Azzouzi AR; Barret E; Villers A; Muir GH; Barber NJ; Bott S; Trachtenberg J; Arumainayagam N; Gaillac B; Allen C; Schertz A; Emberton M
    BJU Int; 2015 Dec; 116(6):888-96. PubMed ID: 24841929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TOOKAD(®) Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer.
    Azzouzi AR; Barret E; Moore CM; Villers A; Allen C; Scherz A; Muir G; de Wildt M; Barber NJ; Lebdai S; Emberton M
    BJU Int; 2013 Oct; 112(6):766-74. PubMed ID: 24028764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medium-term Follow-up of Vascular-targeted Photodynamic Therapy of Localized Prostate Cancer Using TOOKAD Soluble WST-11 (Phase II Trials).
    Noweski A; Roosen A; Lebdai S; Barret E; Emberton M; Benzaghou F; Apfelbeck M; Gaillac B; Gratzke C; Stief C; Azzouzi AR
    Eur Urol Focus; 2019 Nov; 5(6):1022-1028. PubMed ID: 29661587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular-targeted photodynamic therapy with TOOKAD® Soluble in localized prostate cancer: standardization of the procedure.
    Azzouzi AR; Lebdai S; Benzaghou F; Stief C
    World J Urol; 2015 Jul; 33(7):937-44. PubMed ID: 25786708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular targeted photodynamic therapy with TOOKAD® Soluble (WST11) in localized prostate cancer: efficiency of automatic pre-treatment planning.
    Betrouni N; Boukris S; Benzaghou F
    Lasers Med Sci; 2017 Aug; 32(6):1301-1307. PubMed ID: 28569345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endoscopic vascular targeted photodynamic therapy with the photosensitizer WST11 for benign prostatic hyperplasia in the preclinical dog model.
    Chevalier S; Cury FL; Scarlata E; El-Zayat E; Hamel L; Rocha J; Zouanat FZ; Moussa S; Scherz A; Elhilali M; Anidjar M
    J Urol; 2013 Nov; 190(5):1946-53. PubMed ID: 23680311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United States.
    Taneja SS; Bennett J; Coleman J; Grubb R; Andriole G; Reiter RE; Marks L; Azzouzi AR; Emberton M
    J Urol; 2016 Oct; 196(4):1096-104. PubMed ID: 27291652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of localized prostate cancer by vascular-targeted photodynamic therapy with WST11].
    Lebdai S; Martin F; Bigot P; Azzouzi AR
    Prog Urol; 2014 Nov; 24(14):911-4. PubMed ID: 25195031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TOOKAD® Soluble focal therapy: pooled analysis of three phase II studies assessing the minimally invasive ablation of localized prostate cancer.
    Azzouzi AR; Barret E; Bennet J; Moore C; Taneja S; Muir G; Villers A; Coleman J; Allen C; Scherz A; Emberton M
    World J Urol; 2015 Jul; 33(7):945-53. PubMed ID: 25712310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility, safety, and efficacy of salvage radical prostatectomy after Tookad® Soluble focal treatment for localized prostate cancer.
    Lebdai S; Villers A; Barret E; Nedelcu C; Bigot P; Azzouzi AR
    World J Urol; 2015 Jul; 33(7):965-71. PubMed ID: 25614256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses.
    Trachtenberg J; Weersink RA; Davidson SR; Haider MA; Bogaards A; Gertner MR; Evans A; Scherz A; Savard J; Chin JL; Wilson BC; Elhilali M
    BJU Int; 2008 Aug; 102(5):556-62. PubMed ID: 18494829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial.
    Azzouzi AR; Vincendeau S; Barret E; Cicco A; Kleinclauss F; van der Poel HG; Stief CG; Rassweiler J; Salomon G; Solsona E; Alcaraz A; Tammela TT; Rosario DJ; Gomez-Veiga F; Ahlgren G; Benzaghou F; Gaillac B; Amzal B; Debruyne FM; Fromont G; Gratzke C; Emberton M;
    Lancet Oncol; 2017 Feb; 18(2):181-191. PubMed ID: 28007457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of localized prostate cancer using WST-09 and WST-11 mediated vascular targeted photodynamic therapy-A review.
    Kawczyk-Krupka A; Wawrzyniec K; Musiol SK; Potempa M; Bugaj AM; Sieroń A
    Photodiagnosis Photodyn Ther; 2015 Dec; 12(4):567-74. PubMed ID: 26467273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular-targeted Photodynamic Therapy in Unilateral Low-risk Prostate Cancer in Germany: 2-yr Single-centre Experience in a Real-world Setting Compared with Radical Prostatectomy.
    Flegar L; Buerk B; Proschmann R; Propping S; Groeben C; Baunacke M; Herout R; Huber J; Thomas C; Borkowetz A
    Eur Urol Focus; 2022 Jan; 8(1):121-127. PubMed ID: 33602642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expanding indication of padeliporfin (WST11) vascular-targeted photodynamic therapy: results of prostate cancer Latin-American multicenter study.
    Rodriguez-Rivera JA; Rodriguez-Lay R; Zegarra-Montes L; Benzaghou F; Gaillac B; Azzouzi AR; Reis LO; Palma P
    Actas Urol Esp (Engl Ed); 2018 Dec; 42(10):632-638. PubMed ID: 29699883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A model to estimate the outcome of prostate cancer photodynamic therapy with TOOKAD Soluble WST11.
    Betrouni N; Lopes R; Puech P; Colin P; Mordon S
    Phys Med Biol; 2011 Aug; 56(15):4771-83. PubMed ID: 21753234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective close monitoring of the effect of vascular-targeted photodynamic therapy and high intensity focused ultrasound of localized prostate cancer by multiparametric magnetic resonance imaging.
    Solyanik O; Chaloupka M; Clevert DA; Schmidt VF; Ingenerf M; Kazmierczak P; Stief CG; Ricke J; Apfelbeck M
    World J Urol; 2024 Aug; 42(1):462. PubMed ID: 39088086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erectile function after WST11 vascular-targeted photodynamic therapy for low-risk prostate cancer treatment.
    Chelly S; Maulaz P; Bigot P; Azzouzi AR; Lebdai S
    Asian J Androl; 2020; 22(5):454-458. PubMed ID: 31939351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical study of the novel vascular occluding agent, WST11, for photodynamic therapy of the canine prostate.
    Chevalier S; Anidjar M; Scarlata E; Hamel L; Scherz A; Ficheux H; Borenstein N; Fiette L; Elhilali M
    J Urol; 2011 Jul; 186(1):302-9. PubMed ID: 21600602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.